Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
-
Dominant Head moves into Bradman territory with fourth Adelaide ton
-
Arsenal battle to stay top of Christmas charts
-
Mexican low-cost airlines Volaris and Viva agree to merger
-
Border casinos caught in Thailand-Cambodia crossfire
-
Australia's Head slams unbeaten 142 to crush England's Ashes hopes
-
Epstein files due as US confronts long-delayed reckoning
-
'Not our enemy': Rush to rearm sparks backlash in east Germany
-
West Indies 110-0, trail by 465, after Conway's epic 227 for New Zealand
-
Arsonists target Bangladesh newspapers after student leader's death
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
-
Tears at tribute to firefighter killed in Hong Kong blaze
-
Seahawks edge Rams in overtime thriller to seize NFC lead
-
Teenager Flagg leads Mavericks to upset of Pistons
-
Australia's Head fires quickfire 68 as England's Ashes hopes fade
-
Japan hikes interest rates to 30-year-high
-
Brazil's top court strikes down law blocking Indigenous land claims
-
Conway falls for 227 as New Zealand pass 500 in West Indies Test
-
'We are ghosts': Britain's migrant night workers
-
Asian markets rise as US inflation eases, Micron soothes tech fears
-
Giant lanterns light up Christmas in Catholic Philippines
-
TikTok: key things to know
-
Putin, emboldened by Ukraine gains, to hold annual presser
-
Deportation fears spur US migrants to entrust guardianship of their children
-
Upstart gangsters shake Japan's yakuza
-
Trump signs $900 bn defense policy bill into law
-
Stokes's 83 gives England hope as Australia lead by 102 in 3rd Test
-
Go long: the rise and rise of the NFL field goal
-
Australia announces gun buyback, day of 'reflection' after Bondi shooting
-
New Zealand Cricket chief quits after split over new T20 league
-
England all out for 286, trail Australia by 85 in 3rd Test
-
Australian announces gun buyback, day of 'reflection' after Bondi shooting
-
Joshua takes huge weight advantage into Paul fight
-
TikTok signs joint venture deal to end US ban threat
-
Conway's glorious 200 powers New Zealand to 424-3 against West Indies
-
The European "Anti-Trend" Has Arrived
-
LEXINOVA Trading Center Releases New Brand Positioning Strategy Focused on Global Compliance and Institutional-Grade Infrastructure
-
Guardian Metal Resources PLC Announces Pilot Mountain Pre-Feasibility Progress Update
-
WNBA lockout looms closer after player vote authorizes strike
-
Honduras begins partial vote recount in Trump-dominated election
-
Nike shares slump as China struggles continue
-
Hundreds swim, float at Bondi Beach to honour shooting victims
-
Crunch time for EU leaders on tapping Russian assets for Ukraine
-
Pope replaces New York's pro-Trump Cardinal with pro-migrant Chicagoan
-
Trump orders marijuana reclassified as less dangerous drug
-
Rams ace Nacua apologizes over 'antisemitic' gesture furor
-
McIlroy wins BBC sports personality award for 2025 heroics
-
Napoli beat Milan in Italian Super Cup semi-final
-
Violence erupts in Bangladesh after wounded youth leader dies
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
US hosting new Gaza talks to push next phase of deal
Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.
This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value.
"We are pleased to welcome Aloba, Awomolo & Partners as our auditors for the 2024 fiscal year," said a spokesperson for Bionoid Pharma Inc. "Their expertise will be instrumental as we advance our financial reporting standards. Following our recent application to uplist to the OTCQB Venture Market, this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: https://bionoidpharma.com
https://aimaverickintel.com/
OTC Markets: BINP
X (formerly Twitter): @BionoidPharminc
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
A.Malone--AMWN
